If so, CD38-targeted mAbs, such as daratumumab, are approved for the treatment of multiple myeloma. CD38 has also been shown to be highly expressed on activated immune cells, including CD8+ T-cells, CD4+ T-cells, and NK cells. FATE has incorporated the knock-out of CD38 into some of its iPSC-derived products, which uniquely allows for CD38-null, iPSC-derived cells to be combined with CD38-targeted mAbs and avoid fratricide. In one ASH presentation [1], scientists from the company showed that the administration of daratumumab selectively depleted allogeneic CD38+ NK and T-cells and uniquely enabled CD38-null iNK cells to functionally persist through Day 28 compared to non-edited iNK cells. These preclinical data were supported by translational findings from the PhI trial of FT576, its multiplexed-engineered, BCMA-targeted CAR-NK cell product candidate that incorporates the knock-out of CD38, where combination with daratumumab rapidly and selectively eliminated CD38+ patient immune cells through the first month of therapy. The translational findings suggest that following administration of daratumumab, CD38-null iNK cells may avoid rejection by activated host immune cells without requiring conditioning chemotherapy.
Ref:
1 https://ashpublications.org/blood/article/140/Supplement%201/7388/492103/iPSC-Derived-CD38-Null-NK-Cells-in-Combination
Recent NKTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:10:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:04:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 08:22:58 PM
- Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors • GlobeNewswire Inc. • 06/13/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:04:53 PM
- Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Nkarta to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 04/03/2024 08:02:00 PM
- Nkarta Announces Pricing of $240 Million Underwritten Offering • GlobeNewswire Inc. • 03/25/2024 10:30:00 AM
- Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights • GlobeNewswire Inc. • 03/21/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:26:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:32:26 PM
- Nkarta to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 02/28/2024 01:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 02:12:29 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/12/2024 09:20:52 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 11:38:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:45:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:43:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 09:40:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:50:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:49:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:48:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:46:53 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM